All In Biotech

Drug Trial Radar · NCT00806546

An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months

An Open-Label Study to Evaluate the Safety of NP101, a Sumatriptan Iontophoretic Transdermal Patch, in the Treatment of Acute Migraine Over 12 Months

Last checked: Nov 19, 2026Latest source record: Feb 4, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

514

Actual

Start

Feb 2009

Primary completion

May 2011

Study completion May 2011

Sponsor

Lead sponsor
NuPathe Inc.Industry
Sponsor type
Industry
First posted
Dec 11, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will use an open-label design to evaluate the safety of NP101. Adult subjects who meet the enrollment criteria will be treated with NP101 (sumatriptan succinate iontophoretic transdermal patch) for acute migraine attacks over a 12 month period.

Conditions

  • Migraine Disorders

Interventions

  • NP101Drug

    NP101 study patch four hour application

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Subject Self-examination of Skin IrritationTime frame: 24 hours post patch application

Locations

31 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Phoenix, Arizona

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Irvine, California

  • Site not named

    Newport Beach, California

  • Site not named

    San Francisco, California

  • Site not named

    Santa Monica, California

  • Site not named

    Walnut Creek, California

  • Site not named

    Fairfield, Connecticut

  • Site not named

    Hallandale, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Sunrise, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Decatur, Georgia

  • Site not named

    Savannah, Georgia

  • Site not named

    Crestview Hills, Kentucky

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    St Louis, Missouri

  • Site not named

    Mount Vernon, New York

  • Site not named

    Plainview, New York

  • Site not named

    Greensboro, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Cleveland, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Clarksville, Tennessee

  • Site not named

    Dallas, Texas

  • Site not named

    San Antonio, Texas

  • Site not named

    Alexandria, Virginia

  • Site not named

    Virginia Beach, Virginia

  • Site not named

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.